LeMaitre Vascular, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LMAT research report →
Range $86 – $110
Price Chart
About the company
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi.
- CEO
- George W. LeMaitre
- IPO
- 2006
- Employees
- 651
- HQ
- Burlington, MA, US
Get TickerSpark's AI analysis on LMAT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.68B
- P/E
- 26.83
- Fwd P/E
- 26.27
- PEG
- 1.51
- P/S
- 6.36
- P/B
- 3.96
- EV/EBITDA
- 20.45
- Div Yield
- 1.34%
- Gross Margin
- 72.04%
- Op Margin
- 27.73%
- Net Margin
- 23.51%
- ROE
- 15.33%
- ROIC
- 9.26%
Latest fiscal year · YoY change
- Revenue
- $249.60M+13.5%
- Gross Profit
- $178.54M+18.3%
- Op Income
- $67.91M
- Net Income
- $57.73M+31.1%
- EPS
- $2.55+30.1%
- OCF Growth
- +84.1%
- FCF Growth
- +100.4%
- 52W High
- $118.01
- 52W Low
- $73.44
- 50D MA
- $81.01
- 200D MA
- $94.02
- Beta
- 0.49
- RSI (14)
- 34
- Avg Volume
- 278.85K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
LeMaitre delivered 12% organic growth with stronger margins, while guiding to full-year 2026 growth and EPS targets despite FX pressure and acquisition transition costs.· November 4, 2026
- Q3 organic revenue grew 12% on 7% pricing and 5% unit growth; reported revenue grew 11% after a $440,000 FX headwind.
- Gross margin was 71.7%, or 72.4% excluding a $0.5 million FAS-TIP inventory reserve; operating margin was 26%.
- Artegraft and RestoreFlow remained key growth drivers, with Artegraft up 18% overall, international Artegraft sales at $3 million, and RestoreFlow up 34%.
- LeMaitre bought vascular assets from B. Braun for $19.2 million and expects a 18-24 month commercial transition, with some early-year breakage likely.
- Management reiterated full-year 2026 guidance for 11% organic growth, $275.8 million revenue, 72.1% gross margin, $75.4 million operating income, and $2.80 EPS.
Q3 2026 organic revenue growth was 12%, with 7% from price and 5% from units. Reported revenue growth was 11%, with a $440,000 FX headwind; the prior-year comparison excluded a $4.8 million Employee Retention Tax Credit. Gross margin was 71.7% in Q3, up 90 basis points year over year, or 72.4% excluding a $0.5 million inventory reserve; operating margin was 26%, operating income was $17.7 million, net income was $15 million, and fully diluted EPS was $0.65. Free cash flow was $19.7 million and cash and investments ended at $390 million. For full-year 2026, management reiterated 11% organic revenue growth, $275.8 million reported revenue, 72.1% gross margin, $75.4 million operating income, and $2.80 fully diluted EPS.
George LeMaitre emphasized that growth was broad-based and driven by pricing, unit gains, international Artegraft adoption, RestoreFlow growth, and a larger sales force. He framed the B. Braun acquisition as consistent with the company’s long-running strategy of buying niche vascular assets and using its global sales channel to expand them. His tone was confident but pragmatic, especially around the acquisition transition, FDA issues on Artegraft, and the need to keep investing in commercial infrastructure and manufacturing capacity.
Dorian LeBlanc said Q3 reported growth was held back by FX and that gross margin improved to 71.7% due mainly to higher ASPs and lower shipping costs, partly offset by a $0.5 million inventory reserve tied to FAS-TIP discontinuation. He cited $31 million of operating expenses, up 18% year over year, driven by higher rep count, $1.1 million more R&D spend, and added commercial infrastructure; free cash flow was $19.7 million and the company ended September with $390 million in cash and investments. For the full year, he pointed to a 72.1% gross margin target, a $75.4 million operating income target, and a 2026 EPS guide of $2.80, while noting the B. Braun deal is included only modestly in guidance.
Analysts focused heavily on the B. Braun acquisition, asking about asset quality, expected disruption from bundled contracts, and how much revenue might be lost during the transition. Management said the deal had been in gestation for roughly 9-12 months, that some 'breakage' is likely, and that the products are relatively flat at about $9.4-$9.5 million in sales, with B. Braun continuing to sell directly during the transition and LeMaitre entitled to profit sharing. Questions also centered on RestoreFlow processing constraints; George said demand is strong but quality release capacity is limiting sales, and Dorian added inventory has risen to about $14 million from about $12 million at year-end as the company works through the bottleneck.
The call showed continued double-digit organic growth with strong pricing and unit trends, plus especially fast growth in biologics and international opportunities for Artegraft. Management also highlighted healthy profitability, strong cash generation, and a sizable cash balance, while framing the B. Braun acquisition and added warehouses/sales staff as platforms for further expansion.
FX is creating a meaningful reported-growth drag, and management said some of the H2 guide-down is due to the stronger dollar. The B. Braun integration is expected to take 18-24 months, with possible customer breakage, back orders during the manufacturing transfer, and only limited revenue booked in Q4. RestoreFlow is also constrained by internal quality-release capacity, which management acknowledged is leaving sales on the table for now.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 93.1%
- Shares Outstanding
- 22.88M
- Float Shares
- 21.30M
of shares held by institutions
331 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 3.35M | ▲ 72.31K |
| Vanguard Group Inc | 1.62M | ▲ 21.95K |
| First Trust Advisors LP | 1.14M | ▲ 42.13K |
| Congress Asset Management Co | 961.51K | ▼ 2.19K |
| Vanguard Capital Management LLC | 959.53K | ▲ 6.09K |
| Copeland Capital Management, LLC | 924.08K | ▲ 84.62K |
| State Street Corp | 908.36K | ▲ 6.94K |
| Conestoga Capital Advisors, LLC | 878.58K | ▼ 488.93K |
| Price T Rowe Associates Inc | 755.14K | ▲ 460.15K |
| Geode Capital Management, LLC | 736.78K | ▼ 52.05K |
| Vanguard Portfolio Management LLC | 612.56K | ▲ 7.72K |
| Advisors Asset Management, Inc. | 600.33K | ▲ 597.84K |
Held by 322 ETFs
Biggest fund positions in LMAT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | O'Connor John James | other | 3,444 |
| Nov 18, 26 | O'Connor John James | other | 3,444 |
| Sep 3, 26 | Roberts David B | other | 4.352 |
| Sep 3, 26 | Roberts David B | other | 3.632 |
| Sep 3, 26 | Roberts David B | other | 2.126 |
| Sep 3, 26 | Roberts David B | other | 2.126 |
| Sep 3, 26 | Roberts David B | other | 3.576 |
| Sep 3, 26 | Roberts David B | other | 3.157 |
| Sep 3, 26 | Roberts David B | other | 5.287 |
| Sep 3, 26 | Roberts David B | other | 0.345 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LMAT coverage
Recent articles, reports, and earnings notes.
No research on LMAT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LMAT report →LeMaitre Vascular, Inc. (LMAT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 7
LeMaitre to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 6
LeMaitre Vascular Q3 Earnings Call Highlights
marketbeat.com · Nov 4
LeMaitre Vascular (LMAT) Misses Q3 Earnings Estimates
zacks.com · Nov 4
LeMaitre Q3 2026 Financial Results
globenewswire.com · Nov 4
Dividend Income Report: +15.25% And A Listener's Portfolio Roast
seekingalpha.com · Oct 31
LeMaitre Will Announce Third Quarter 2026 Earnings Results on November 4, 2026
globenewswire.com · Oct 12
LeMaitre Vascular: The Q2 Miss Hides A Stronger Acquisition Machine
seekingalpha.com · Oct 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.